Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Aslan Pharmaceuticals Ltd ADR

Healthcare US ASLN

NoneUSD
0.00(0%)

Last update at 2024-09-11T10:46:57.651070Z

Day Range

--
LowHigh

52 Week Range

0.394.26
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap10.07M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-34.89343M
  • Revenue TTM12.00M
  • Revenue Per Share TTM0.69
  • Gross Profit TTM 79.82M
  • Diluted EPS TTM-1.9

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -51.28320M -31.59058M -16.97129M -46.65754M -42.17116M
Minority interest 0.00000M 0.27M 0.30M 32.17M 1.07M
Net income -51.38242M -34.70922M -17.90621M -47.06554M -42.18560M
Selling general administrative 9.88M 11.83M 7.17M 8.51M 10.51M
Selling and marketing expenses - - - - -
Gross profit - 0.00000M 0.00000M 2.59M 0.00000M
Reconciled depreciation 0.33M 0.28M 0.30M 0.45M 0.24M
Ebit -47.88249M -33.84645M -16.48330M -45.57897M -41.67925M
Ebitda -47.60751M -32.03736M -15.72396M -45.75592M -41.43749M
Depreciation and amortization 0.27M 1.81M 0.76M -0.17695M 0.24M
Non operating income net other - - - 0.00000M 0.00000M
Operating income -47.88249M -33.84645M -16.48330M -45.57897M -42.34807M
Other operating expenses 47.88M 33.85M 16.48M 48.58M 42.35M
Interest expense 3.68M 1.86M 1.25M 0.90M 0.49M
Tax provision 0.10M 0.00000M 0.00000M 0.41M 0.01M
Interest income 0.35M 0.00022M 0.00059M 0.15M 0.27M
Net interest income -3.32123M -1.86074M -1.24674M -0.75100M -0.22357M
Extraordinary items - - - 0.00000M 0.00000M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense 0.10M 3.12M 0.93M 0.41M 0.01M
Total revenue 0.00000M 0.00000M 0.00000M 3.00M 0.00000M
Total operating expenses 47.88M 33.85M 16.48M 48.17M 42.35M
Cost of revenue - 0.00000M 0.00000M 0.41M 0.00000M
Total other income expense net -3.40071M 2.26M -0.48799M -1.07856M 0.18M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops -51.38242M -31.59058M -16.97129M -47.06554M -42.18560M
Net income applicable to common shares -51.38242M -31.32162M -16.19789M -1450.51500M -42.18560M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 24.63M 61.19M 94.52M 16.08M 23.35M
Intangible assets - 5.84M - 0.00016M 0.00284M
Earning assets - - - - -
Other current assets 2.71M 3.98M 3.61M 0.51M 0.07M
Total liab 37.91M 52.82M 37.21M 26.23M 23.95M
Total stockholder equity -13.28693M 8.37M 57.30M -10.45297M -1.67735M
Deferred long term liab - - - - 0.00000M
Other current liab 3.17M 2.42M 0.22M 0.27M 3.25M
Common stock 63.93M 63.02M 63.02M 61.83M 61.37M
Capital stock 63.93M 63.02M 63.02M 61.83M 61.37M
Retained earnings -321.06724M -278.38675M -227.00433M -195.68271M -179.48483M
Other liab - - - 0.11M 13.40M
Good will - -5.83016M - - 0.00000M
Other assets 0.00000M - - 0.10M 5.28M
Cash 21.25M 56.90M 90.17M 14.32M 22.20M
Cash and equivalents - - - - -
Total current liabilities 13.11M 23.16M 6.36M 10.66M 5.38M
Current deferred revenue - - 2.82M 4.28M -
Net debt 5.57M -19.28144M -59.11154M 4.93M -3.81617M
Short term debt 2.03M 7.96M 0.20M 3.79M 0.26M
Short long term debt 1.80M 7.75M - 3.52M 0.00000M
Short long term debt total 26.83M 37.62M 31.06M 19.26M 18.39M
Other stockholder equity 219.77M 223.91M 221.47M 123.58M 116.50M
Property plant equipment - 0.29M 0.23M 0.48M 22.95M
Total current assets 24.13M 60.88M 93.78M 15.50M 22.27M
Long term investments 0.24M 0.00859M 0.49M 0.00000M 0.20M
Net tangible assets - 8.36M 57.29M -10.45312M -50.32700M
Short term investments - - 0.00000M 0.14M 0.00000M
Net receivables 0.17M - - 0.53M -
Long term debt 24.80M 29.66M 30.86M 15.18M 17.63M
Inventory - - - - 0.00000M
Accounts payable 7.92M 12.78M 3.12M 2.32M 1.87M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 24.07M -0.17895M -0.17895M -0.17895M -0.05508M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - 61.83M 61.37M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 0.00172M 8.59M 0.00996M 0.10M 0.11M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 0.50M 0.31M 0.74M 0.58M 1.08M
Capital lease obligations 0.23M 0.22M 0.20M 0.55M 0.76M
Long term debt total - - - - 542.82M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.41M -0.02815M 0.00093M 0.00538M -23.09429M
Change to liabilities 9.67M 0.80M 0.45M -106.23700M 1.42M
Total cashflows from investing activities 0.41M -0.02815M 0.00093M 0.17M -23.09429M
Net borrowings 4.74M 11.86M -0.20261M 92.75M 4.06M
Total cash from financing activities 4.72M 109.87M 7.17M 19.09M 40.90M
Change to operating activities -0.31618M -4.91784M -0.01646M -1.30100M -0.22060M
Net income -51.28320M -31.59058M -16.97129M -46.65754M -42.17116M
Change in cash -33.26589M 75.84M -7.87866M -6.70587M -21.66431M
Begin period cash flow 90.17M 14.32M 22.20M 28.91M 50.57M
End period cash flow 56.90M 90.17M 14.32M 22.20M 28.91M
Total cash from operating activities -38.40525M -33.99555M -15.05299M -25.80271M -39.46951M
Issuance of capital stock 0.00000M 101.56M 7.64M 14.73M 42.18M
Depreciation 0.33M 0.28M 0.30M 0.45M 0.24M
Other cashflows from investing activities 0.35M 0.02M 0.00477M 0.08M -0.01113M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - - 0.00000M 0.00000M
Change to account receivables - - -0.52884M -0.52884M -0.52884M
Sale purchase of stock - - - 450.09M 1257.58M
Other cashflows from financing activities 4.99M 16.45M -0.26723M 4.60M -1.28051M
Change to netincome 3.29M 1.16M 0.94M 748.20M 1.28M
Capital expenditures 0.03M 0.05M 0.00506M 0.00299M 23.08M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital 9.35M -4.12062M -0.09759M -3.48609M 1.14M
Stock based compensation 1.98M 2.19M 0.35M 0.04M 1.29M
Other non cash items 1.22M 1.86M 1.25M 0.82M 0.22M
Free cash flow -38.43236M -34.04436M -15.05805M -25.80570M -62.55267M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASLN
Aslan Pharmaceuticals Ltd ADR		 - -% - - - 0.94 2.14 0.74 -0.2158
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Aslan Pharmaceuticals Ltd ADR

3 Temasek Avenue, Singapore, Singapore, 039190

Key Executives

Name Title Year Born
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, CEO & Exec. Director 1973
Mr. Kiran Kumar Asarpota COO & Head of Fin. 1979
Mr. Ben Goodger Gen. Counsel 1963
Mr. Stephen Doyle Chief Bus. Officer 1973
Charlie Hsu Investor Relations Director NA
Chi-Chin Wang IR & Corp. Devel. Director NA
Dr. Alexandre Kaoukhov M.D. Chief Medical Officer 1974
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, CEO & Executive Director 1973
Mr. Kiran Kumar Asarpota COO & Head of Finance 1979
Mr. Ben Goodger General Counsel 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.